Overview A Study of of HOT1030 in Patients With Advanced Solid Tumors Status: Recruiting Trial end date: 2023-06-30 Target enrollment: Participant gender: Summary A Phase 1, Open-label, Dose-escalation Study of the Safety and Pharmacokinetics of HOT-1030 in Patients with Advanced Solid Tumors Phase: Phase 1 Details Lead Sponsor: Huabo Biopharm Co., Ltd.